Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jan-Feb;8(1):85-106. doi: 10.1002/wnan.1355. Epub 2015 Aug 21. Review.

2.

Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.

Pan D, Sanyal N, Schmieder AH, Senpan A, Kim B, Yang X, Hu G, Allen JS, Gross RW, Wickline SA, Lanza GM.

Nanomedicine (Lond). 2012 Oct;7(10):1507-19. doi: 10.2217/nnm.12.27. Epub 2012 Jun 18.

3.

Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.

Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT.

Biomaterials. 2012 Nov;33(33):8632-40. doi: 10.1016/j.biomaterials.2012.08.005. Epub 2012 Aug 24.

4.

Lipid prodrug nanocarriers in cancer therapy.

Mura S, Bui DT, Couvreur P, Nicolas J.

J Control Release. 2015 Jun 28;208:25-41. doi: 10.1016/j.jconrel.2015.01.021. Epub 2015 Jan 21. Review.

PMID:
25617724
5.

Lipidic prodrug approach for improved oral drug delivery and therapy.

Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A.

Med Res Rev. 2019 Mar;39(2):579-607. doi: 10.1002/med.21533. Epub 2018 Oct 15. Review.

PMID:
30320896
6.

Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Kraft JC, Freeling JP, Wang Z, Ho RJ.

J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25. Review.

7.

Liposomes and inorganic nanoparticles for drug delivery and cancer imaging.

Heneweer C, Gendy SE, Peñate-Medina O.

Ther Deliv. 2012 May;3(5):645-56. Review.

PMID:
22834408
8.

Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.

Pan D, Schmieder AH, Wang K, Yang X, Senpan A, Cui G, Killgore K, Kim B, Allen JS, Zhang H, Caruthers SD, Shen B, Wickline SA, Lanza GM.

Theranostics. 2014 Mar 11;4(6):565-78. doi: 10.7150/thno.7581. eCollection 2014.

9.

Lipid-based drug carriers for prodrugs to enhance drug delivery.

Zaro JL.

AAPS J. 2015 Jan;17(1):83-92. doi: 10.1208/s12248-014-9670-z. Epub 2014 Oct 1. Review.

10.

Advancement in integrin facilitated drug delivery.

Arosio D, Casagrande C.

Adv Drug Deliv Rev. 2016 Feb 1;97:111-43. doi: 10.1016/j.addr.2015.12.001. Epub 2015 Dec 10. Review.

PMID:
26686830
11.

Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN.

Nanomedicine. 2016 Jan;12(1):201-11. doi: 10.1016/j.nano.2015.10.003. Epub 2015 Oct 27.

12.

Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations.

Wang H, Chen J, Xu C, Shi L, Tayier M, Zhou J, Zhang J, Wu J, Ye Z, Fang T, Han W.

Theranostics. 2017 Aug 23;7(15):3638-3652. doi: 10.7150/thno.20028. eCollection 2017.

13.

Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles.

Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY.

J Microencapsul. 2009 Dec;26(8):734-47. doi: 10.3109/02652040902746679.

PMID:
19888882
14.

Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.

Cheng L, Hostetler KY, Lee J, Koh HJ, Beadle JR, Bessho K, Toyoguchi M, Aldern K, Bovet JM, Freeman WR.

Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4138-44.

15.

Liver-targeted drug delivery using HepDirect prodrugs.

Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA.

J Pharmacol Exp Ther. 2005 Feb;312(2):554-60. Epub 2004 Aug 31.

PMID:
15340017
16.

Targeted lipid based drug conjugates: a novel strategy for drug delivery.

Vadlapudi AD, Vadlapatla RK, Kwatra D, Earla R, Samanta SK, Pal D, Mitra AK.

Int J Pharm. 2012 Sep 15;434(1-2):315-24. doi: 10.1016/j.ijpharm.2012.05.033. Epub 2012 Jun 9.

17.

Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.

Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM.

Expert Rev Med Devices. 2007 Mar;4(2):137-45. Review.

PMID:
17359221
18.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Pérez-Herrero E, Fernández-Medarde A.

Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Review.

19.

Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.

Ali Khan A, Mudassir J, Mohtar N, Darwis Y.

Int J Nanomedicine. 2013;8:2733-44. doi: 10.2147/IJN.S41521. Epub 2013 Jul 26. Review.

20.

A strategy for oral chemotherapy via dual pH-sensitive polyelectrolyte complex nanoparticles to achieve gastric survivability, intestinal permeability, hemodynamic stability and intracellular activity.

Deng L, Dong H, Dong A, Zhang J.

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):107-17. doi: 10.1016/j.ejpb.2015.10.010. Epub 2015 Oct 26.

PMID:
26515259

Supplemental Content

Support Center